Skip to main content

Emapalumab Disease Interactions

There are 2 disease interactions with emapalumab.

Major

Immunosuppressive agents (applies to emapalumab) infections

Major Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents. Patients receiving immunosuppressants are at increased risk of developing bacterial, viral, fungal, and protozoal infections, and new or reactivated viral infections including opportunistic infections. Caution should be exercised when considering their use in patients with severe or chronic infections. It is recommended to interrupt therapy in patients who develop a new infection while undergoing treatment and to monitor these patients closely for any sign or symptom indicative of infection.

References

  1. "Product Information. Rapamune (sirolimus)." Wyeth-Ayerst Laboratories PROD (2001):
  2. "Product Information. Soliris (eculizumab)." Alexion Pharmaceuticals Inc (2007):
  3. "Product Information. Nulojix (belatacept)." Bristol-Myers Squibb (2011):
  4. "Product Information. Aubagio (teriflunomide)." Genzyme Corporation (2012):
  5. "Product Information. Entyvio (vedolizumab)." Takeda Pharmaceuticals America (2014):
  6. "Product Information. Mycophenolic Acid (mycophenolic acid)." Apotex Corporation (2017):
  7. "Product Information. Gamifant (emapalumab)." Sobi Inc (2018):
  8. "Product Information. Lupkynis (voclosporin)." Aurinia Pharma (2021):
  9. "Product Information. Saphnelo (anifrolumab)." Astra-Zeneca Pharmaceuticals (2021):
View all 9 references
Moderate

Emapalumab-lzsg (applies to emapalumab) vaccination

Moderate Potential Hazard, Moderate plausibility.

Do not administer live or live attenuated vaccines to patients receiving emapalumab-lzsg and for at least 4 weeks after the last dose of emapalumab-lzsg. Exercise care as the safety of immunization with live vaccines during or following therapy has not been studied.

References

  1. "Product Information. Gamifant (emapalumab)." Sobi Inc (2018):

Emapalumab drug interactions

There are 91 drug interactions with emapalumab.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer